The Lack of Ad Hoc Neuropsychological Assessment in Adults with Neurofibromatosis: A Systematic Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Apr 9

PMID 38592693

Authors

Giuseppa Maresca

Carmen Bonanno

Isabella Veneziani

Viviana Lo Buono

Desiree Latella

Angelo Quartarone

Silvia Marino

Caterina Formica

Affiliations

Soon will be listed here.

Abstract

Neurofibromatosis Type 1 (NF1) is a genetic autosomal dominant disorder that affects both the central and peripheral nervous systems. Children and adolescents with NF1 commonly experience neuropsychological, motor, and behavioral deficits. The cognitive profile hallmark of this disorder includes visuospatial and executive function impairments. These cognitive disorders may persist into adulthood. This study aims to analyze previous research studies that have described cognitive dysfunctions in adults with NF1. The purpose of this analysis is to review the neuropsychological and psychological assessment methods used. A total of 327 articles were identified based on the search terms in their titles and abstracts. The evaluation was conducted by scrutinizing each article's title, abstract, and text. Only 16 articles were found to be eligible for inclusion based on the pre-defined criteria. The selected studies primarily focus on the development of diagnostic protocols for individuals with NF1. The management of NF1 disease requires a multidisciplinary approach to address symptoms, preserve neurological functions, and ensure the best possible quality of life. However, cognitive impairment can negatively affect psychological well-being. This study suggested that cognitive functions in NF1 patients were not tested using specific measures, but rather were evaluated through intelligence scales. Additionally, the findings revealed that there is no standardized neuropsychological assessment for adults with NF1. To address this gap, it would be helpful to create a specific neuropsychological battery to study cognitive function in NF1 patients during clinical studies. This battery could also serve as a tool to design models for cognitive rehabilitation by using reliable and sensitive measures of cognitive outcomes.

References

Miguel C, Chaim-Avancini T, Silva M, Louza M . Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review. Neuropsychiatr Dis Treat. 2015; 11:815-21. PMC: 4378869. DOI: 10.2147/NDT.S75038. View

Hellebrekers D, van Abeelen S, Catsman C, van Kuijk S, Laridon A, Klinkenberg S . Cognitive and behavioral functioning in two neurogenetic disorders; how different are these aspects in Duchenne muscular dystrophy and Neurofibromatosis type 1?. PLoS One. 2022; 17(10):e0275803. PMC: 9551631. DOI: 10.1371/journal.pone.0275803. View

Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman J . Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005; 65(2):205-11. DOI: 10.1212/01.wnl.0000168830.79997.13. View

Champion J, Rose K, Payne J, Burns J, North K . Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2014; 56(5):468-74. DOI: 10.1111/dmcn.12361. View

Piscitelli O, Digilio M, Capolino R, Longo D, Di Ciommo V . Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning. Dev Med Child Neurol. 2011; 54(1):49-51. DOI: 10.1111/j.1469-8749.2011.04139.x. View

Molinari M, Petrosini L, Misciagna S, Leggio M . Visuospatial abilities in cerebellar disorders. J Neurol Neurosurg Psychiatry. 2004; 75(2):235-40. PMC: 1738892. View

Torres Nupan M, Velez Van Meerbeke A, Lopez Cabra C, Herrera Gomez P . Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr. 2017; 5:227. PMC: 5670111. DOI: 10.3389/fped.2017.00227. View

Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, MUDD S . Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet. 1998; 102(5):591-7. DOI: 10.1007/s004390050746. View

Fjermestad K, Nyhus L, Kanavin O, Heiberg A, Hoxmark L . Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls. J Genet Couns. 2018; 27(5):1102-1110. DOI: 10.1007/s10897-018-0229-5. View

10.

Lehtonen A, Howie E, Trump D, Huson S . Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2012; 55(2):111-125. DOI: 10.1111/j.1469-8749.2012.04399.x. View

11.

Beaussart M, Barbarot S, Mauger C, Roy A . Systematic Review and Meta-analysis of Executive Functions in Preschool and School-Age Children With Neurofibromatosis Type 1. J Int Neuropsychol Soc. 2018; 24(9):977-994. DOI: 10.1017/S1355617718000383. View

12.

Hyman S, Gill D, Shores E, Steinberg A, Joy P, Gibikote S . Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology. 2003; 60(7):1139-45. DOI: 10.1212/01.wnl.0000055090.78351.c1. View

13.

Pavol M, Hiscock M, Massman P, Moore Iii B, Foorman B, Meyers C . Neuropsychological function in adults with von Recklinghausen's neurofibromatosis. Dev Neuropsychol. 2006; 29(3):509-26. DOI: 10.1207/s15326942dn2903_8. View

14.

Iheanacho I, Yoo H, Yang X, Dodman S, Hughes R, Amin S . Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review. Neurol Sci. 2021; 43(2):1281-1293. PMC: 8789731. DOI: 10.1007/s10072-021-05361-5. View

15.

Zhu Y, Ghosh P, Charnay P, Burns D, Parada L . Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002; 296(5569):920-2. PMC: 3024710. DOI: 10.1126/science.1068452. View

16.

Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J . Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology. 2003; 61(12):1725-8. DOI: 10.1212/01.wnl.0000098881.95854.5f. View

17.

Lester E, DiStefano S, Mace R, Macklin E, Plotkin S, Vranceanu A . Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Gen Hosp Psychiatry. 2019; 62:72-78. DOI: 10.1016/j.genhosppsych.2019.12.001. View

18.

Struemph K, Watts A, Wolters P, Tamula M, Baldwin A, Widemann B . Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. Am J Med Genet A. 2021; 188(2):488-497. DOI: 10.1002/ajmg.a.62544. View

19.

Schutze M, Costa D, Jardim de Paula J, Malloy-Diniz L, Malamut C, Mamede M . Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1. PLoS One. 2018; 13(9):e0203520. PMC: 6128556. DOI: 10.1371/journal.pone.0203520. View

20.

Payne J, Haebich K, Mackenzie R, Walsh K, Hearps S, Coghill D . Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. J Atten Disord. 2019; 25(8):1177-1186. DOI: 10.1177/1087054719894384. View